764Risk Factors for Failure of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Management of Staphylococcus aureus Bacteremia (SAB)

Risk Factors for Failure of OPAT (Outpatient Parenteral Antimicrobial Therapy) in Veterans with Staphylococcus aureus Bacteremia

To identify risk factors for failure of OPAT (outpatient parenteral antimicrobial therapy) among veterans with SAB (Staphylococcus aureus bacteremia), a retrospective review was conducted of all patients receiving OPAT for SAB between 01/2011-09/2013 at a large, tertiary-care VA (Veterans’ Affairs) medical center. Treatment failure was defined as incomplete therapy, therapy extension, infection...

Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service.

OBJECTIVES We describe failure rates of 198 patients with bone and joint infection (BJI), including prosthetic joint infection and diabetic foot osteomyelitis, managed through the Glasgow centre for outpatient parenteral antibiotic therapy (OPAT) over a period of 4 years. Outcomes following initial intravenous antimicrobial therapy and a median follow-up time of 60 weeks are described. PATIEN...

Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin vs. Non-Vancomycin Anti-MRSA Therapy

1300OPAT Administration in the Homeless Population

Background. Outpatient parenteral antimicrobial therapy (OPAT) is increasingly used to treat serious infections. The IDSA recommends assessing “the functioning of utilities, safety issues, cleanliness, substance abuse, access to transportation and social strife” prior to initiation of OPAT. Because of these foreseen barriers, OPAT is infrequently offered to homeless patients, and little is know...

730A Retrospective Comparison of Self – Administered Ceftriaxone vs Cefazolin for Methicillin-Susceptible Staphylococcus Aureus Bacteremia in an Outpatient Antibiotic Therapy Setting.

Background. MSSA bacteremia is a common cause of community-acquired and hospital-acquired infections with significant morbidity and mortality. Ceftriaxone is a third generation cephalosporin with activity against gram positive and gram negative aerobic bacteria including MSSA. It is well tolerated and offers significant cost reduction with its once daily dosing in the outpatient setting. Althou...